Surrozen (NASDAQ:SRZN – Get Free Report) and Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.
Analyst Recommendations
This is a summary of recent ratings and price targets for Surrozen and Prelude Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 1 | 1 | 4 | 1 | 2.71 |
| Prelude Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Surrozen currently has a consensus price target of $48.33, indicating a potential upside of 106.20%. Prelude Therapeutics has a consensus price target of $8.75, indicating a potential upside of 168.40%. Given Prelude Therapeutics’ higher possible upside, analysts clearly believe Prelude Therapeutics is more favorable than Surrozen.
Risk & Volatility
Surrozen has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Insider and Institutional Ownership
66.6% of Surrozen shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Surrozen and Prelude Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $11.51 million | 23.64 | -$242.03 million | ($40.55) | -0.58 |
| Prelude Therapeutics | $12.14 million | 21.43 | -$99.50 million | ($0.73) | -4.47 |
Prelude Therapeutics has higher revenue and earnings than Surrozen. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Surrozen and Prelude Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | -2,885.33% | N/A | -93.62% |
| Prelude Therapeutics | N/A | -75.35% | -44.39% |
Summary
Prelude Therapeutics beats Surrozen on 10 of the 15 factors compared between the two stocks.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
About Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
